"External Quality Assessment in Medical Laboratories" - differences with other PT testing programs

JC Libeer
Brussels, Belgium
EQA versus PT

- The term PT in laboratory medicine is commonly used in North America.
  - Proficiency testing (PT) focuses essentially on laboratory performance evaluations especially for regulatory purposes.
From EQAS to EQAP

- EQAS: External Quality Assessment Schemes
- EQAP: External Quality Assurance Programs

EQAP

- EQAP is an interlaboratory comparison designed and operated to assure one or more of following aspects:
  - Participant performance evaluation (analytical performance, test interpretation, advice to the clinician on laboratory requests and on diagnosis
  - Vigilance of IVD’s
  - Continuous education, training and help

The primary intention of the activities of an EQAP in laboratory medicine shall be to support quality improvements of the service provided by participating laboratories for the benefits of the patients.

(IFCC Guidelines for the Requirements for the Competence of EQAP organizers 2002)
5.6.4 The laboratory shall participate in interlaboratory comparisons such as those organized by external quality assessment schemes. Laboratory management shall monitor the results of external quality assessment and participate in the implementation of corrective actions when control criteria are not fulfilled. Interlaboratory comparison shall be in substantial agreement with ISO/IEC Guide 43-1.

External quality assessment programmes should, as far as possible, provide clinically relevant challenges that mimic patient samples and have the effect of checking the entire examination process, including pre- and post-examination procedures.
Medical laboratories — Particular requirements for quality and competence

Laboratoires d'analyses de biologie médicale — Exigences particulières concernant la qualité et la compétence
contributing to patient care
Introduction: *Medical laboratory services are essential to patient care...*

4.1.2: *Medical laboratory services, including appropriate interpretation and advisory services, shall be designed to meet the needs of patients and all clinical personnel responsible for patient care*
4.12.4: Laboratory management shall implement quality indicators for systematically monitoring and evaluating the laboratory’s contribution to patient care.

Laboratory management shall ensure that the medical laboratory participates in quality improvement activities that deal with relevant areas and outcomes of patient care.
4.14.1: "The internal audit shall progressively address these elements and emphasize areas critically important to patient care."

4.15.1: "In order to ensure their continuing suitability and effectiveness in support of patient care,...

- i) quality indicators for monitoring the laboratory’s contribution to patient care"
4.15.3: The quality and appropriateness of the laboratory’s contribution to patient care shall, to the extent possible, be monitored and evaluated objectively.

5.2.1: The laboratory shall have space allocated so that its workload can be performed without compromising the quality of work, quality control procedures, safety of personnel or patient care services.
5.8: Reporting of results:
e) Date and time of primary sample collection, when available and relevant to patient care, and time of receipt by the laboratory

5.8.7 The laboratory shall have procedures for immediate notification of a physician (or other clinical responsible for patient care) when examination results for critical properties fall within established « alert » or « critical » intervals.
5.8.11 Laboratory management, in consultation with the requesters, shall establish turnaround times for each of its examinations. A turnaround time shall reflect clinical needs.

This does not mean that the clinical personnel are to be notified of all delays in examinations, but only in those situations where the delay could compromise patient care.
« Patient care in ISO 15189 »

- Annex B: Recommendations for protection of laboratory information systems (LIS)

Reference to « patient care » 4X
EQA/PT ORGANIZERS

- Medical laboratories
  - Professional organisations
  - Scientific societies
  - Governmental organisations
  - IVD manufacturers
- Other type of laboratories
  - International and national scientific organisations (institutions)
  - Commercial organisations
  - Accreditation bodies
Professional & Scientific EQA organizers versus commercial EQA organizers

- Is there a specific role to play by professional and scientific EQA organisations?
- Is there a specific role to play by IVD manufacturers organizing EQA schemes?
EQA from IVD manufacturers (1)

- Organizer of regular EQA schemes with several materials
- Link with the producer of kits and reagents
- Extra service for users of the same internal QC material
- Only own QC materials are used
- No real patient material
EQA from IVD manufacturers (2)

- Especially activity in clinical chemistry and immunoassays
- Large groups, in general good service
- Free participation
- Educational, no sanctions
- Feedback from a steering committee (expert board)?
- THESE SCHEMES FOCUS ON ANALYTICAL QUALITY
“Non-commercial” EQA schemes

PT schemes
- Mandatory
- Linked to a licence
- Repressive (sanctions)
- Acceptability limits based on “state of the art”
- Static: no incentive for quality improvement
- Follow-up: “the bad and the good boys”

External quality assessment => external quality assurance schemes
- Can be mandatory or free
- Can be linked to a license
- Essentially educational
- Dynamic: incentives for quality improvement – tools for problem related schemes
- (EQAP approach)
Inconvenience of PT schemes

- “Bad boys” are punished
- Everybody is happy with the “good boys”
  - But: are the good boys as good as they look?
- “Impression” of the potential capability of laboratories to perform these tests
- No link with patient samples analysis
EQAP covers more than EQA

- Participant performance evaluation
- Method performance evaluation
- Continuous education tool
- Analytical performance and clinical outcome evaluation
- Support for internal QC
- Training & help
- Promotion of standardisation efforts
- Quality improvement of patient results & interpretation
- .....
EQAP covers more than EQA: new item of interest

EQA for the interpretation of results
External Quality Assurance Programs

- Broad panel of schemes covering all aspects of laboratory medicine
  - Preparation of own control materials
  - Or
  - Sharing sample preparation
- Attention for new fields, new tests
- Fields for which there is no interest from “commercial” organizers
External Quality Assurance Programs

- MUST FOCUS ON CLINICAL OUTCOME AND NOT ONLY ON ANALYTICAL RESULTS
  - Including pre- and post analytical EQA
  - Including difficult samples
  - Mimic as much as possible patient samples
  - Attention for quality management of new applications (POCT, NPT)
  - Acceptability limits may be based on EBM, biological requirements,..
Pre-analytical EQA: examples

- Examination of sample deficiencies based on data from participants (SEQC experience)
- EQA on appropriate sample package
- Paper challenges with a clinical case and evaluation of an appropriate tests request
- Distribution of not appropriate sample material (these samples are expected not to be analysed)
Preanalytical quality control program – an overview of results (2001–2005 summary)

- **105 LABORATORIES**: 4,715,132 tubes → 32,977 (0.699%) REJECTS
  - EDTA/SERUM (75.6% of all samples) → 55.8% of all rejects
  - 81% of rejects due to:
    - Specimen not received → 37.5%
    - HEMOLYSIS → 29.3% = 9,662 samples!
    - Clotted sample → 14.4%
- **About 30% of ALL rejects due to HEMOLYSIS**

A nasal swab is submitted to the laboratory with clinical information “possible anthrax”. No other information provided. What action would your laboratory undertake with this sample?

<table>
<thead>
<tr>
<th></th>
<th>Action Description</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Set-up and Culture. Read at 24 hours.</td>
<td>22%</td>
</tr>
<tr>
<td>B</td>
<td>Do not process. Destroy swab. Report: “Do not perform this test”.</td>
<td>0%</td>
</tr>
<tr>
<td>C</td>
<td>Do not process. Contact physician.</td>
<td>34%</td>
</tr>
<tr>
<td>D</td>
<td>Do not process. Seal for public health. Contact Public Health.</td>
<td>78%</td>
</tr>
</tbody>
</table>

CMPT M013; November 2001
Example of educational EQAS

*Cyclospora cayetanensis:*

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>N labs</td>
<td>255</td>
<td>263</td>
<td>239</td>
</tr>
<tr>
<td>Cyclospora</td>
<td>135</td>
<td>214</td>
<td>192</td>
</tr>
<tr>
<td>(52.9%)</td>
<td>(81.4%)</td>
<td>(80.3%)</td>
<td></td>
</tr>
<tr>
<td>No parasites found</td>
<td>52</td>
<td>10</td>
<td>18</td>
</tr>
<tr>
<td>(20.4%)</td>
<td>(3.8%)</td>
<td>(7.8%)</td>
<td></td>
</tr>
</tbody>
</table>

Results in the Belgian EQAS programmes
Appropriate EQA material

- Performances of lyophilized materials do not always reflect performances in patient samples
- Some materials are scarce (IgM samples for serology)
- Realistic patient material
- Virtual microscopy samples
Bias of cholesterol methods against the RMV in lyophilised control samples

![Bar chart showing the bias of cholesterol methods against the RMV in lyophilised control samples. Each bar represents a method (M1, M2, M3, and All methods) with bars showing the percentage bias. The y-axis represents the percentage bias ranging from -12% to 0%, while the x-axis represents the methods. The chart indicates that all methods have a negative bias, with M3 having the least bias.](image-url)
Bias of cholesterol methods against the RMV in frozen patient samples
PT/EQA Specimens Can be Realistic
Post-Analytical EQA

- Interpretation of analytical results
- Which information is given to the clinician?
- Correct use of reference values
Appropriate reference values check

- HbA1c: all methods in use are DCTT converted after IFCC calibration
  ⇒ Reference values should be the same in all laboratories (4-6%)

Real life: reported reference values

<table>
<thead>
<tr>
<th>3.0-5.8</th>
<th>3.5-6.2</th>
<th>4.5-6.8</th>
<th>5.1-6.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1-5.4</td>
<td>4.0-6.0</td>
<td>4.8-6.0</td>
<td>6.0-8.0</td>
</tr>
</tbody>
</table>
**Post-analytical EQAS**

- **Paper challenges on interpretation of results**

Informatie van WIV-ILP:

Staal C/1486 (Volwassen man): staal klaar voor gebruik (5.0 ml) - Staal C/4187 (Volwassen man): staal klaar voor gebruik (10.0 ml). De stalen moeten aan -20°C bewaard worden indien de analyse niet gebeurd op de dag van ontvangst.

---

**ALBUMIN (00380)**

<table>
<thead>
<tr>
<th>Kit</th>
<th>JOHNSON &amp; JOHNSON CALBE / 5 x 50 slides (8196057)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methode</td>
<td>reflectance photometry (BCG) (oldmeth=004)</td>
</tr>
<tr>
<td>Meetapparaat</td>
<td>JOHNSON &amp; JOHNSON EKTACHEM/VITROS 750 C</td>
</tr>
</tbody>
</table>

**Waardev**

<table>
<thead>
<tr>
<th>Value</th>
<th>Operator</th>
<th>Eenheid</th>
<th>Verwijder test en parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.9</td>
<td></td>
<td>g/dl</td>
<td></td>
</tr>
</tbody>
</table>

**Diagnose**

<table>
<thead>
<tr>
<th>Geen</th>
<th>Normaal</th>
</tr>
</thead>
</table>

**Vrije tekst**

<table>
<thead>
<tr>
<th>Geen</th>
<th>Normaal</th>
<th>Verhoogd</th>
<th>Verlaagd</th>
</tr>
</thead>
</table>

---

ALBUMIN (00380)

SUBMIT
Combined analytical and post-analytical exercise

The Norwegian Quality Improvement of Primary Care Laboratories

The aim of the quality assurance system is that tests should be requested, analysed and interpreted in accordance with defined professional standards and in accordance with the patients needs for diagnosis, treatment and management.
EQAS for virology

Sample S/5339 and S/5340 were taken to the same patient with an interval of 4 weeks; Pregnancy wish in the scope of IVF for a woman, 35 years old. Request for CMV diagnosis

Requested results:
On each sample: total antibodies, IgG, IgG avidity, IgM

Test interpretation: positive, negative, borderline

Combined interpretation for both samples:
Negative
Seroconversion
Recent infection (< 3 months)
Infection > 3 months
Reactivity
Others
EQAS for hemato-oncology: example

- Paper challenge with
- Patient history and clinical context
- Results of cell counting
- Results of flow cytometry
- Translocations
Problem-related EQA schemes

- Schemes focus on different aspects of the test so that participants can have information on these aspects were there is a problem
Problem related EQA: sperm staining procedure

- Send two smears for morphology
- Collect stained smears
- Define criteria for acceptable results
- Evaluation of staining by 3 experts
- Report to participants

No “commercial” scheme will do this!
Method performance evaluation

- QCMD survey NG08: two samples with DNA from other Neisseria strains
- *N. lactamica* in sample NG08-06 and *N. cinerea* in sample NG08-09
- All participants using Roche Amplicor have false positive results for both samples
**EQA ON INTERFERENCE BY HEMOLYSIS (B EQA)**

- Participants were asked to
  - score for the presence of hemolysis:
    - absent (-) – weak (+) – moderate (++) – strong (+++)
  - to report the H-index if available and the instrument used

(Courtesy of Christel Van Campenhout and Nicole Hamers)
<table>
<thead>
<tr>
<th>System</th>
<th>Normal</th>
<th>Hemolyzed</th>
<th>DIF (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GGT Mixel.</td>
<td>24.8</td>
<td>21</td>
<td>-19.4</td>
</tr>
<tr>
<td>GGT Roche-SZASZ</td>
<td>20</td>
<td>13.5</td>
<td>-35.7</td>
</tr>
<tr>
<td>GGT OCD</td>
<td>22.0</td>
<td>23</td>
<td>-13.0</td>
</tr>
<tr>
<td>GGT Siemens (Dade)</td>
<td>24</td>
<td>24.5</td>
<td>2.1</td>
</tr>
<tr>
<td>GGT Coulter</td>
<td>21.3</td>
<td>19</td>
<td>-10.8</td>
</tr>
<tr>
<td>GGT Roche-IFCC</td>
<td>21</td>
<td>12.9</td>
<td>-36.6</td>
</tr>
</tbody>
</table>
A dream for EQA schemes of the future?
EQA in hematology: case 2014/3

- Clinical history
- Samples
- Data
- Instructions for replying
Clinical history (example)

- All materials were drawn from the same patient: woman 79 years old.
- Since a few weeks abdominal pain. Routine examination revealed a lymphocytosis.
Question (example)

- Perform those analysis in order to give relevant clinical information for the clinician
Samples

- (Serum tube)
- EDTA blood tube
- (Virtual samples)
EQA examinations

- Flow cytometry: markers of lymphocytosis
  - T-cell markers performed
  - Results
Available data

- Report of the cell counting
  - Select your analyzer
  - View of the report
Virtual peripherical blood smear
## WBC Differentiation in Smear H 3456

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Count</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrophile segmentkerniger</td>
<td>55</td>
<td>55%</td>
</tr>
<tr>
<td>Neutrophile staafkerniger</td>
<td>6</td>
<td>0%</td>
</tr>
<tr>
<td>Eosinophile segmentkerniger</td>
<td>3</td>
<td>3%</td>
</tr>
<tr>
<td>Basophile segmentkerniger</td>
<td>2</td>
<td>2%</td>
</tr>
<tr>
<td>Lymfocyten</td>
<td>26</td>
<td>26%</td>
</tr>
<tr>
<td>Reactionele lymfocyten</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Monocyten</td>
<td>8</td>
<td>8%</td>
</tr>
<tr>
<td>Promyelocyten</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Neutrophile myelocyten</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Neutrophile metamyelocyten</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Blasten</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Lymfomateuze cellen</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Andere cellen</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Erythroblasten</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td><strong>TOTAAL</strong></td>
<td><strong>100</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>
# WBC differentiation in smear H 3456

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Count</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrofiele segmentkernen</td>
<td>55</td>
<td>55 %</td>
</tr>
<tr>
<td>Neutrofiele staafkernen</td>
<td>6</td>
<td>0 %</td>
</tr>
<tr>
<td>Eosinoefiele segmentkernen</td>
<td>3</td>
<td>3 %</td>
</tr>
<tr>
<td>Basofiele segmentkernen</td>
<td>2</td>
<td>2 %</td>
</tr>
<tr>
<td>Lymfocyten</td>
<td>26</td>
<td>26 %</td>
</tr>
<tr>
<td>Reactionele lymfocyten</td>
<td>0</td>
<td>0 %</td>
</tr>
<tr>
<td>Monocyten</td>
<td>8</td>
<td>8 %</td>
</tr>
<tr>
<td>Promyeloocyten</td>
<td>0</td>
<td>0 %</td>
</tr>
<tr>
<td>Neutrofiele myelocyten</td>
<td>0</td>
<td>0 %</td>
</tr>
<tr>
<td>Neutrofiele metamyelocyten</td>
<td>0</td>
<td>0 %</td>
</tr>
<tr>
<td>Blasten</td>
<td>0</td>
<td>0 %</td>
</tr>
<tr>
<td>Lymfomateuze cellen</td>
<td>0</td>
<td>0 %</td>
</tr>
<tr>
<td>Andere cellen</td>
<td>0</td>
<td>0 %</td>
</tr>
<tr>
<td>Erytroblasten</td>
<td>0</td>
<td>0 %</td>
</tr>
<tr>
<td><strong>TOTAAL</strong></td>
<td><strong>100</strong></td>
<td><strong>100 %</strong></td>
</tr>
</tbody>
</table>

**Lymphocytes:**
A4c, A4d, A7a, B2e, .................;

**Monocytes:**
A6e, D2f, ...

Every cell can be checked by the EQAS organizer
Hidden additional information

Clinical chemistry examinations and results

Bone marrow results or data
You may open one or more drawers and use the information. Only open those that you consider as essential for your final advice.
## Evaluation externe de la qualité en hématologie : Médullogramme

<table>
<thead>
<tr>
<th>Contrôle</th>
<th>Uitstrijkje</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Frottis sanguin</strong></td>
<td><strong>Bloeduitstrijkje</strong></td>
</tr>
<tr>
<td>Morphologie des globules rouges et des plaquettes</td>
<td>Morfologie rode bloedcellen en bloedplaatjes</td>
</tr>
<tr>
<td>Galerie des globules blancs</td>
<td>Fotogalerij witte bloedcellen</td>
</tr>
<tr>
<td>Renseignements patient</td>
<td>Gegevens patiënt</td>
</tr>
<tr>
<td>Résultats</td>
<td>Resultaten</td>
</tr>
<tr>
<td><strong>Médullogramme</strong></td>
<td><strong>Medullogram</strong></td>
</tr>
<tr>
<td>Coloration May-Grünwald Giemsa</td>
<td>May-Grünwald Giemsa kleuring</td>
</tr>
<tr>
<td>Examens complémentaires</td>
<td>Bijkomende onderzoeken</td>
</tr>
<tr>
<td>Renseignements patient</td>
<td>Gegevens patiënt</td>
</tr>
<tr>
<td>Résultats</td>
<td>Resultaten</td>
</tr>
</tbody>
</table>
Virtual bone marrow smear

Medullogram "Uitstrijkje"

Virtual bone marrow

Full screen
Terug naar begin
Examens complémentaires - Cytochimie : Perls

"Contrôle"
Information received by the EQA organizer

- Participant ID
- Information on used technology for the requested analytes performed on the EQA samples
- Results of analysis
- Formulated final advice
- Logging of opened drawer(s)
EQAP is more than PT and traditional EQA!
An important role can be played by
Thank You!
Goodbye.
I’ll miss you